# De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

> **NCT07153757** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 2934 (estimated)

## Conditions studied

- Breast Cancer Early Stage Breast Cancer (Stage 1-3)

## Interventions

- **DRUG:** Endocrine Therapy of Physician's Choice

## Key facts

- **NCT ID:** NCT07153757
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2033-09-01
- **Final completion:** 2033-09-01
- **Target enrollment:** 2934 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07153757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07153757, "De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07153757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*